Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 local clinical study of Solucin® neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NET)

Next Previous
Trial Profile

A phase 2 local clinical study of Solucin® neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NET)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lu-177 octreotide (Primary)
  • Indications Gastro-enteropancreatic neuroendocrine tumour; Pancreatic cancer
  • Focus Therapeutic Use

Most Recent Events

  • 04 Sep 2019 New trial record
  • 02 Sep 2019 According to an ITM Solucin, DuChemBio Co Media release, the companies plan to initiate a local clinical study for ITM's Solucin TRT which is expected to begin recruiting patients in 2020. The concept of this study is based on ITM's Phase III clinical trial COMPETE.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top